UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2020
Commission File Number: 001-39131
LIMINAL BIOSCIENCES INC.
(Translation of registrant’s name into English)
440 Armand-Frappier Boulevard, Suite 300
Laval, Québec
H7V 4B4
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: ☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INCORPORATION BY REFERENCE
This Report on Form 6-K (the “Report”) and Exhibits 99.2, 99.3 and 99.6 to this Report are hereby expressly incorporated by reference into the registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on December 23, 2019 (File no. 333-235692).
Management and Board Changes
On November 12, 2020, the Company announced that Mr. Kenneth Galbraith tendered his resignation as Chief Executive Officer and member of its Board for personal reasons, effective November 13, 2020. Mr. Bruce Pritchard, Chief Operating Officer, Small Molecules Therapeutics, and Mr. Patrick Sartore, Chief Operating Officer, Plasma-Derived Therapeutics, will assume the roles of Chief Executive Officer and President, respectively, effective November 13, 2020.
EXHIBIT LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | Liminal BioSciences Inc. |
| | | |
Date: November 12, 2020 | | | | By: | | /s/ Kenneth Galbraith |
| | | | | | Name | | Kenneth Galbraith |
| | | | | | Title: | | Chief Executive Officer |
